行情

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

2.660
+0.090
+3.50%
盘后: 2.610 -0.05 -1.88% 16:13 10/18 EDT
开盘
2.510
昨收
2.570
最高
2.750
最低
2.380
成交量
37.25万
成交额
--
52周最高
24.45
52周最低
2.160
市值
915.87万
市盈率(TTM)
-0.0011
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PSTV 新闻

  • 欧洲等市场需求飙升 特斯拉延长Model3在美交付时间
  • TechWeb.1小时前
  • 美国电子烟相关肺病病例接近1500例
  • 央视.1小时前
  • 美国加州失业率降至4%创纪录 贫富差距仍不容乐观
  • 中国新闻网.2小时前
  • 全球威胁开始消退 欧元有望进一步攀升
  • 新浪财经综合.2小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

PSTV 简况

Plus Therapeutics, Inc., formerly Cytori Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.
展开

Webull提供Plus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。